Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FITCELL + compound methoxyphenamine
- Development stage
- Unknown
- Lead developer
- Shanghai ChangZheng Hospital
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Oral, Inhalation
01
Overview
This combination therapy consists of inhaled mesenchymal stem cell-derived exosomes (specifically the product FITCELL) and oral compound methoxyphenamine capsules (marketed as Asmei). The exosomes are delivered via nebulization to the lungs, where they are intended to exert anti-inflammatory and tissue-repair effects by modulating the local immune environment and reducing airway hyperresponsiveness. Compound methoxyphenamine is a fixed-dose combination containing methoxyphenamine hydrochloride (a bronchodilator), noscapine (an antitussive), chlorpheniramine maleate (an antihistamine), and anhydrous caffeine. This therapeutic regimen is being evaluated by Shanghai Changzheng Hospital for the treatment of post-infectious cough (PIC), aiming to address both the underlying inflammatory damage and the acute symptoms of persistent coughing following respiratory infections.
- Brand names
- Asmei
- Other names
- Mesenchymal stem cell-derived exosomes + compound methoxyphenamineMesenchymal stem cell derived exosome nebulization combined with compound methoxyphenamine capsule
02
Targets
ADOR (Adenosine receptors)SIGMAR1 (Sigma non-opioid intracellular receptor 1)ADRB2 (β2)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on FITCELL + compound methoxyphenamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FITCELL + compound methoxyphenamine.